The order prohibits the compounder from making any sterile drugs until it completes corrective actions.
The agency alleges the compounding pharmacy manufactured and distributed drugs that were tainted because the drugs were made in unsanitary conditions.
According to the FDA, Pharm D Solutions continued to produce the drugs despite several warnings from the agency.
“Despite previous warnings and promises to make corrections, Pharm D Solutions and its owners placed patients and their health at significant risk. Compounders must follow quality manufacturing practices to ensure consumers are not exposed to potentially harmful drugs,” said Donald Ashley, director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
J&J to cut 61 jobs in New Jersey
Mallinckrodt to spin off generics unit
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
